Cerebellar ataxia is an umbrella term used to describe a variety of movement disorders caused by dysfunction of the cerebellum, a part of the brain responsible for balance, coordination, and fine motor control. These disorders can range from mild to severe, and the most common symptoms are gait difficulty, limb incoordination, slurred speech, fatigue, poor balance, and tremor. In some cases, the disorder can be inherited, but in many it can result from a traumatic brain injury, stroke, infection, tumor, exposure to toxins or other illnesses. One of the most common forms of cerebellar ataxia is hereditary ataxia, which affects more than 40,000 people in the United States. There are more than 40 different types of hereditary ataxia, each caused by a mutation in a different gene. The most common forms of hereditary ataxia are spinocerebellar ataxia, Friedreich's ataxia, and ataxia-telangiectasia. Other forms of cerebellar ataxia, such as sensory ataxia and myoclonic ataxia, are caused by damage to the sensory and motor systems, respectively. Sensory ataxia is caused by a loss of sensation in the limbs, while myoclonic ataxia is characterized by involuntary jerking movements. Cerebellar ataxia is a disorder that can cause significant disability, as it typically affects speech, balance, coordination, and fine motor control. In severe cases, it may be necessary to receive assistance with activities of daily living such as bathing, dressing, and eating. Treatment often includes a combination of physical therapy, occupational therapy, medications and even surgery depending on the severity of the condition. With proper management, many individuals with cerebellar ataxia can lead productive and independent lives.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States